Market Research Logo

EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2026

EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2026

Summary

Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining.

To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the diagnosed prevalent cases (symptomatic) as well as data for the severity segmentation of the diagnosed prevalent cases (symptomatic) from primary market research. In addition, the forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases (symptomatic) of hand OA will increase from 17,948,101 cases in 2016 to 20,413,591 cases in 2026 at an annual growth rate (AGR) of 1.37%, the diagnosed prevalent cases (symptomatic) of knee OA will increase from 15,235,201 cases in 2016 to 17,641,626 cases in 2026 at an AGR of 1.58%, and the diagnosed prevalent cases (symptomatic) of hip OA will increase from 3,361,141 cases in 2016 to 3,867,480 cases in 2026 at an AGR of 1.51%.Scope

  • The Osteoarthritis (OA) EpiCast Report provides an overview of the risk factors and global trends of hand OA, knee OA, and hip OA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • It includes a 10-year epidemiological forecast for the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA segmented by age (beginning at 18 years and older) and sex in these markets. The diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA are further segmented by severity using Kellgren-Lawrence (KL) grading into mild (KL = 2), and moderate to severe (KL = 3 to 4).
  • The OA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The OA EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global OA market.
  • Quantify patient populations in the global OA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for OA therapeutics in each of the markets covered.
  • Understand magnitude of OA population by disease severity.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Osteoarthritis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for OA (2016-2026)
3.5.1 Total Prevalent Cases (Radiographic) of Hand OA
3.5.2 Total Prevalent Cases (Symptomatic) of Hand OA
3.5.3 Diagnosed Prevalent Cases (Symptomatic) of Hand OA
3.5.4 Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA
3.5.5 Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA
3.5.6 Diagnosed Prevalent Cases (Symptomatic) of Hand OA by Severity
3.5.7 Total Prevalent Cases (Radiographic) of Knee OA
3.5.8 Total Prevalent Cases (Symptomatic) of Knee OA
3.5.9 Diagnosed Prevalent Cases (Symptomatic) of Knee OA
3.5.10 Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA
3.5.11 Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA
3.5.12 Diagnosed Prevalent Cases (Symptomatic) of Knee OA by Severity
3.5.13 Total Prevalent Cases (Radiographic) of Hip OA
3.5.14 Total Prevalent Cases (Symptomatic) of Hip OA
3.5.15 Diagnosed Prevalent Cases (Symptomatic) of Hip OA
3.5.16 Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA
3.5.17 Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA
3.5.18 Diagnosed Prevalent Cases (Symptomatic) of Hip OA by Severity
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 High-Prescribing Physician Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for OA
Table 2: Severity Scoring System for Classifying the Hand, Knee, and Hip OA Using the KL Grading Scale.
Table 3: 7MM, Total Prevalent Cases (Radiographic) of Hand OA, Both Sexes, Ages ≥18 Years, N, Selected Years 2016-2026
Table 4: 7MM, Total Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, Selected Years 2016-2026
Table 5: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, Selected Years 2016-2026
Table 6: 7MM, Total Prevalent Cases (Radiographic) of Knee OA, Both Sexes, Ages ≥18 Years, N, Selected Years 2016-2026
Table 7: 7MM, Total Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, Selected Years 2016-2026
Table 8: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, Selected Years 2016-2026
Table 9: 7MM, Total Prevalent Cases (Radiographic) of Hip OA, Both Sexes, Ages ≥18 Years, N, Selected Years 2016-2026
Table 10: 7MM, Total Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, Selected Years 2016-2026
Table 11: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, Selected Years 2016-2026
Table 12: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2017
1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, 2016 and 2026
Figure 2: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, 2016 and 2026
Figure 3: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, 2016 and 2026
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence (Symptomatic) (%), Hand OA, Men and Women, Ages ≥18 Years, 2016
Figure 5: 7MM, Age-Standardized Diagnosed Prevalence (Symptomatic) (%), Knee OA, Men and Women, Ages ≥18 Years, 2016
Figure 6: 7MM, Age-Standardized Diagnosed Prevalence (Symptomatic) (%), Hip OA, Men and Women, Ages ≥18 Years, 2016
Figure 7: 7MM, Sources Used to Forecast Total Prevalent Cases (Radiographic), Hand OA
Figure 8: 7MM, Sources Used to Forecast Total Prevalent Cases (Symptomatic), Hand OA
Figure 9: 7MM, Sources Used to Forecast Total Prevalent Cases (Radiographic), Knee OA
Figure 10: 7MM, Sources Used to Forecast Total Prevalent Cases (Symptomatic), Knee OA
Figure 11: 7MM, Sources Used to Forecast Total Prevalent Cases (Radiographic), Hip OA
Figure 12: 7MM, Sources Used to Forecast Total Prevalent Cases (Symptomatic), Hip OA
Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2016
Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2016
Figure 15: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hand OA by Severity, Both Sexes, Ages ≥18 Years, N, 2016
Figure 16: 7MM, Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2016
Figure 17: 7MM, Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2016
Figure 18: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Knee OA by Severity, Both Sexes, Ages ≥18 Years, N, 2016
Figure 19: 7MM, Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2016
Figure 20: 7MM, Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2016
Figure 21: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hip OA by Severity, Both Sexes, Ages ≥18 Years, N, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report